US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Alzamend Neuro Inc (ALZN)
Alzamend Neuro Inc (ALZN) ニュース

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALZN

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/17	05 : 30	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/14	21 : 00	Business Wire	Alzamend Neuro Announces Initial Closing of Private Placement	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/14	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/11	06 : 06	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/11	05 : 30	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/10	19 : 30	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/10	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/10	05 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/09	21 : 00	Business Wire	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/08	05 : 31	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/08	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2024/05/07	21 : 00	Business Wire	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program	NASDAQ:ALZN	Alzamend Neuro Inc
2024/03/08	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2024/02/03	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2024/01/06	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2023/12/16	06 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALZN	Alzamend Neuro Inc
2023/12/11	22 : 00	Business Wire	Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	NASDAQ:ALZN	Alzamend Neuro Inc
2023/11/20	22 : 00	Business Wire	Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	NASDAQ:ALZN	Alzamend Neuro Inc
2023/11/17	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2023/11/16	22 : 00	Business Wire	Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	NASDAQ:ALZN	Alzamend Neuro Inc
2023/11/13	22 : 00	Business Wire	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	NASDAQ:ALZN	Alzamend Neuro Inc
2023/10/31	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2023/10/30	21 : 00	Business Wire	Alzamend Neuro Announces Reverse Stock Split	NASDAQ:ALZN	Alzamend Neuro Inc
2023/10/23	21 : 00	Business Wire	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001	NASDAQ:ALZN	Alzamend Neuro Inc
2023/10/02	21 : 00	Business Wire	Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	NASDAQ:ALZN	Alzamend Neuro Inc
2023/09/30	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2023/09/27	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALZN	Alzamend Neuro Inc
2023/09/23	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALZN	Alzamend Neuro Inc
2023/09/22	21 : 00	Business Wire	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement	NASDAQ:ALZN	Alzamend Neuro Inc
2023/09/14	06 : 09	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALZN	Alzamend Neuro Inc

Showing the most relevant articles for your search:NASDAQ:ALZN

1 2 3 4 5 6 7 次へ >>

Procure Space ETF

Cyon Exploration

Wacker Chemie Ag Muenchen (PK)

Societe Generale Effekten

VanEck Gaming ETF

SPDR Russell 1000 Low Vo...

ABANCA Corporacin Bancaria

Sharc International Syst... (QB)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約